Candel Therapeutics, Inc. CADL Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Candel Therapeutics, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Candel Therapeutics, Inc.'s accrued expenses?
- Candel Therapeutics, Inc. (CADL) reported accrued expenses of $89K in Q1 2026.
- How has Candel Therapeutics, Inc.'s accrued expenses changed year-over-year?
- Candel Therapeutics, Inc.'s accrued expenses decreased by 96.7% year-over-year, from $2.72M to $89K.
- What is the long-term trend for Candel Therapeutics, Inc.'s accrued expenses?
- Over 5 years (2020 to 2025), Candel Therapeutics, Inc.'s accrued expenses has grown at a -13.8% compound annual growth rate (CAGR), from $187K to $89K.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.